BioSpace News Archive

Telix Pharmaceuticals Limited and GenesisCare today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate cancer.

Agios Pharmaceuticals, Inc. announced the grant of inducement equity awards outside of the Company’s 2013 Stock Incentive Plan to its newly appointed Chief Financial Officer, Cecilia Jones.

Sciwind Biosciences and SynerK announced today that they have entered into a research partnership to jointly discover and develop new therapeutics based on small interfering RNA (siRNA) technology to treat liver and metabolic diseases marked by unmet medical needs.

Angel Pharmaceuticals Ltd. (“Angel Pharma”), a clinical-stage biopharmaceutical company, today announced that the IND application for mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation (CDE) to initiate a Phase 1/1b clinical trial in China.

AnPac Bio-Medical Science Co., Ltd. announced that on September 26, 2022, the Company and a group of nine institutional and individual investors have signed legally binding agreements for the investment in the Company by the Investors of approximately $3.67 Million.